Mesalazine

The colonic mucosa of patients with active UC has high levels of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). Mesalazine can inhibit the synthesis of prostaglandins in a dose-dependent manner and reduce the release of PGE2 in the human colonic mucosa. In addition, mesalazine can also inhibit the lipoxygenase activity of neutrophils. Adding mesalazine to culture human colonic mucosal cells can inhibit two important inflammatory mediators—chemotactic LTB4 and leukotrienes in a dose-effect manner. At high doses, mesalazine can inhibit certain functions of human neutrophils, such as migration, degranulation, phagocytosis and synthesis of oxygen free radicals. In addition, mesalazine can also inhibit the synthesis of platelet activity factor (PAF), which plays an important role in inflammation. It works best on the connective tissue of the inflamed bowel wall. For ulcerative colitis, ulcerative proctitis, and Crohn's disease.

It has a significant inhibitory effect on intestinal wall inflammation. Mesalazine can inhibit the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediator leukotrienes, thereby significantly inhibiting intestinal mucosal inflammation.

In 25kg fibre drum

EP10